PRJNA527923
mouse gut metagenome Metagenome
The global prevalence of nonalcoholic steatohepatitis (NASH) increases incredibly. NASH ends up to advanced liver disease, which is highly threatening to human health. Currently, treatment of NASH is very limited. Acetyl-CoA carboxylases (ACC1/ACC2) are proved as effective drug targets for NASH. As known, alterations of gut microbiota were closely intertangled with the progression of NASH but effects of ACC inhibitor on gut microbiota is still unknown. We treated mice with WZ66 and collect content from cecum after sacrifice, then, 16S rRNA gene sequencing analysis was performed to assess the influences of WZ66 on gut microbiota.